Health and Fitness Health and Fitness
Fri, December 5, 2008
[ Fri, Dec 05th 2008 ] - Market Wire
Ore Pharmaceuticals Announces Completion of Multi .. inical Phase 1 Trial; Presents GL1001 Preclinical
[ Fri, Dec 05th 2008 ] - Market Wire
Company Profile for Alphatec Spine
[ Fri, Dec 05th 2008 ] - Market Wire
FDA Advisory Committee to Discuss Genzyme s Synvisc-One PMA on Tuesday
[ Fri, Dec 05th 2008 ] - Market Wire
Candela to Seek Stockholder Approval Prior to Certain Issuances of Preferred Stock
[ Fri, Dec 05th 2008 ] - Market Wire
Cytokinetics, Inc.: Cytokinetics Announces Precli .. a Regarding Ispinesib to Be Presented at the 31st
[ Fri, Dec 05th 2008 ] - Market Wire
St. Jude Medical Announces Neuromodulation Divisi .. rand Identity at 12th Annual North American Neuro
[ Fri, Dec 05th 2008 ] - Market Wire
Resumen: Publicados en el New England Journal of .. an la eficacia de Viread en el tratamiento de la
Thu, December 4, 2008
[ Thu, Dec 04th 2008 ] - Market Wire
PDL BioPharma, Inc.: David Parkinson, M.D. Elected to Facet Biotech's Board of Directors
[ Thu, Dec 04th 2008 ] - Market Wire
NitroMed Receives Unsolicited Acquisition Proposal from Deerfield Management
[ Thu, Dec 04th 2008 ] - Market Wire
AmSurg Corp. to Present at the RBC Capital Markets 2008 Healthcare Conference
[ Thu, Dec 04th 2008 ] - Market Wire
Assisted Living Concepts, Inc.: Assisted Living C .. pts, Inc. to Attend New York Investor Conferences
[ Thu, Dec 04th 2008 ] - Market Wire
SCOR: Moody's upgrades SCOR to 'A2'
[ Thu, Dec 04th 2008 ] - Market Wire
Alnylam Selected as 2009 Technology Pioneer by the World Economic Forum
[ Thu, Dec 04th 2008 ] - Market Wire
Jonathan Lewis, MD, PhD, Appointed to Scientific .. ory Council of the Hope Funds for Cancer Research
[ Thu, Dec 04th 2008 ] - Market Wire
Osiris Completes Enrollment in First Worldwide Phase III Stem Cell Trial
[ Thu, Dec 04th 2008 ] - Market Wire
Novelos Therapeutics and Academic Collaborators P .. Posters at 2008 AACR Tumor Immunology Conference
[ Thu, Dec 04th 2008 ] - Market Wire
Tesetaxel, a Leading Oral Taxane in Clinical Deve .. ation as an Orphan Drug for Treatment of Patients
[ Thu, Dec 04th 2008 ] - Market Wire
Hi-Tech Pharmacal to Release First Quarter Earnings and Hold Conference Call on December 9, 2008
[ Thu, Dec 04th 2008 ] - Market Wire
BioSante Pharmaceuticals Signs Elestrin " Marketing Agreement with Azur Pharma
[ Thu, Dec 04th 2008 ] - Market Wire
ImmunoGen, Inc. Announces Webcast of Panel Sessio .. he RBC Capital Markets 2008 Healthcare Conference
[ Thu, Dec 04th 2008 ] - Market Wire
Sirona Announces $50 Million Share Repurchase Authorization
[ Thu, Dec 04th 2008 ] - Market Wire
Centene Corporation Names Aaron W. Brace as President and CEO of South Carolina Subsidiary
Wed, December 3, 2008
[ Wed, Dec 03rd 2008 ] - Market Wire
AngioDynamics Implements Leadership Development P .. eliminary Fiscal Second Quarter Financial Results
[ Wed, Dec 03rd 2008 ] - Market Wire
Alphatec Spine to Present at the RBC Healthcare Conference
[ Wed, Dec 03rd 2008 ] - Market Wire
Biomoda, Inc.: NM Tech, Biomoda Win Legislative Support for Lung Cancer Screening
[ Wed, Dec 03rd 2008 ] - Market Wire
Zila to Report Fiscal 2009 First Quarter Financia .. s and Host Investor Conference Call on December 8
[ Wed, Dec 03rd 2008 ] - Market Wire
PerkinElmer Announces Strategic Acquisition of Arnel Inc.
[ Wed, Dec 03rd 2008 ] - Market Wire
CytoDyn Awarded Global Patents For Modernizing The Treatment of Infectious Diseases
[ Wed, Dec 03rd 2008 ] - Market Wire
Aspect Medical Systems Repurchases $35 Million of Its 2.5% Convertible Senior Notes Due 2014
[ Wed, Dec 03rd 2008 ] - Market Wire
Synta Pharmaceuticals to Participate in the RBC Capital Markets Healthcare Conference

Synta Pharmaceuticals to Participate in the RBC Capital Markets Healthcare Conference


Published on 2008-12-03 08:21:41 - Market Wire
  Print publication without navigation


LEXINGTON, Mass.--([ BUSINESS WIRE ])--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that President and CEO Safi Bahcall, Ph.D., will participate in a panel discussion titled Tackling Tumors at the 2008 RBC Capital Markets Healthcare Conference on Wednesday, December 10 at 1:30 pm (ET) at The Westin New York at Times Square.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, [ www.syntapharma.com ].

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma. For more information, please visit [ www.syntapharma.com ].

Contributing Sources